32797-61-8

Basic information

• Product Name: 4-AMINOMETHYL BENZAMIDINE DIHYDROCHLORIDE
• Synonyms: 4-AMINOMETHYL BENZAMIDINE, 2HCL;4-AMINOMETHYL BENZAMIDINE DIHYDROCHLORIDE;4-Aminomethyl-benzamidine
• CAS NO: 32797-61-8
• Molecular Formula: C₈H₁₁N₃
• Molecular Weight: 222.11
• Mol File: 32797-61-8.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 283.8°C at 760 mmHg
• Flash Point: 125.5°C
• Appearance: /
• Vapor Pressure: 0.00309mmHg at 25°C
• CAS DataBase Reference: 4-AMINOMETHYL BENZAMIDINE DIHYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-AMINOMETHYL BENZAMIDINE DIHYDROCHLORIDE(32797-61-8)
• EPA Substance Registry System: 4-AMINOMETHYL BENZAMIDINE DIHYDROCHLORIDE(32797-61-8)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36
• Safety Statements: 26
• Hazardous Substances Data: 32797-61-8(Hazardous Substances Data)

Usage

General Description

4-Aminomethyl benzamidine dihydrochloride, also known by its product name B5775, is a chemical compound with a molecular formula of C8H13Cl2N3. This water-soluble chemical is usually available as a white crystalline powder. Commonly used in various scientific and industrial applications, this compound features as an ingredient in different research activities, especially in the field of biochemistry. Its essential features include its role as a damnacanthal mimetic and as an inhibitor of kinases and proteases. However, like many other chemical compounds, it needs to be handled with caution due to its potential hazards.

InChI:InChI=1/C8H11N3.2ClH/c9-5-6-1-3-7(4-2-6)8(10)11;;/h1-4H,5,9H2,(H3,10,11);2*1H

Upstream product

• 84466-87-5 4-(azidomethyl)benzonitrile 
• 162696-15-3 N-Boc-4-aminomethyl benzamidine 
• 66389-80-8 tert-butyl N-[(4-cyanophenyl)methyl]carbamate 
• 63914-51-2 [(4-cyanophenyl)methyl]-carbamic acid phenylmethyl ester 
• 17201-43-3 4-cyanobenzyl bromide 
• 10406-25-4 4-aminobenzyl cyanide 
• 328552-93-8 4-(aminomethyl)-N-hydroxybenzene-1-carboximidamide 
• 366023-02-1 (4-carbamimidoyl-benzyl)-carbamic acid benzyl ester 

Downstream Products

• 1449371-74-7 C₂₀H₂₂N₄O₂S 
• 1449371-68-9 C₂₇H₂₅N₁₁O₄S 
• 1449371-67-8 C₁₆H₁₈N₆O₃S 
• 1449371-69-0 C₂₁H₂₀N₆O₃S 
• 1449371-73-6 C₁₄H₁₂N₆O₃ 
• 1456890-24-6 N-(4-carbamimidoylbenzyl)-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-5-carboxamide 

Relevant articles and documents

Protein-Templated Formation of an Inhibitor of the Blood Coagulation Factor Xa through a Background-Free Amidation Reaction

Protein-templated reactions enable the target-guided formation of protein ligands from reactive fragments, ideally with no background reaction. Herein, we investigate the templated formation of amides. A nucleophilic fragment that binds to the coagulation factor Xa was incubated with the protein and thirteen differentially activated dipeptides. The protein induced a non-catalytic templated reaction for the phenyl and trifluoroethyl esters; the latter was shown to be a completely background-free reaction. Starting from two fragments with millimolar affinity, a 29 nm superadditive inhibitor of factor Xa was obtained. The fragment ligation reaction was detected with high sensitivity by an enzyme activity assay and by mass spectrometry. The reaction progress and autoinhibition of the templated reaction by the formed ligation product were determined, and the structure of the protein–inhibitor complex was elucidated.

Thrombin inhibitors having a lactam at P3

The present invention provides compounds having a lactam ring at P3 and at P1 have a six-membered heterocyclic ring having two ring nitrogen ring atoms and the remainder of the ring atoms carbon atoms. These compounds have biological activity as active and potent inhibitors of thrombin. Their pharmaceutically acceptable salts, pharmaceutical compositions thereof and methods of using these compounds and pharmaceutical compositions comprising these compounds as therapeutic agents for treatment of disease states in mammals which are characterized by abnormal thrombosis are also described.

Non-covalent inhibitors of urokinase and blood vessel formation

Novel compounds having activity as non-covalent inhibitors of urokinase and having activity in reducing or inhibiting blood vessel formation are provided. These compounds have Pi a group having an amidino or guanidino moiety or derivative thereof. These compounds are useful in vitro for monitoring plasminogen activator levels and in vivo in treatment of conditions which are ameliorated by inhibition of or decreased activity of urokinase and in treating pathologic conditions wherein blood vessel formation is related to a pathologic condition.